Rituximab is effective in about one half of patients with indolent lymphoma. Even these patients relapse and develop rituximab resistance. To increase potency and circumvent resistance, the anti-lymphoma effects of rituximab, an anti-CD20 MAb 1 , combined with chLym-1 2 , an anti-HLA-DR MAb, were assessed in human lymphoma cell lines by examining growth inhibition and cell death, apoptosis induction, ADCC 3 and CDC 4 . There were additive effects in all assays and synergism in cell lines, such as B35M, which displayed resistance to either MAb alone. In B35M cells, combined rituximab and chLym-1 induced a 27-fold direct reduction in viable cells, whereas equivalent concentrations of rituximab or chLym-1 alone induced only a 1-fold and 10-fold reduction in viable cells, respectively. Because these results occurred at MAb concentrations readily achievable in patients, they suggest that this combination immunotherapy regimen may increase the potency and range of effectiveness of these MAbs in lymphoma patients.
INTRODUCTION
Lymphoma treatment has traditionally relied on chemotherapeutic drugs used singly or in combination. While combination chemotherapy is generally more effective than monotherapy, it has been less successful in indolent lymphoma as most patients eventually relapse and succumb to the disease [1] .
Monoclonal antibodies (MAbs 1 ) for immunotherapy provide high specificity for lymphoma antigens, alternate and potent mechanisms of cytotoxicity, and widespread tolerability in patients [2, 3] . Rituximab has been incorporated into treatment regimens for B-cell lymphoma because it has efficacy as a single agent against indolent lymphomas, inducing a therapeutic response in approximately 50% of previously chemotherapy-treated patients with only mild toxicity [4] . Upon binding to CD20, an antigen present exclusively on mature normal and malignant B cells, rituximab activates several direct and indirect anti-lymphoma mechanisms, including growth inhibition, apoptosis, antibody dependent cellular cytotoxicity (ADCC 3 ), and complement-dependent cytotoxicity (CDC 4 ) [5] [6] [7] [8] . Like chemotherapy, however, patients eventually become resistant to rituximab immunotherapy [9, 10] .
When rituximab and cyclophosphamide, doxorubicin, vincristine, prednisone chemotherapy (CHOP 5 ) have been combined in clinical trials, more patients, of all lymphoma subtypes, experienced a therapeutic response of longer duration [11] [12] [13] , presumably related to the advantage of different mechanisms of drug action [14] [15] [16] [17] . However, at least 20% of patients with aggressive lymphoma [13] and 40% of those with indolent lymphoma [11] do not experience a complete response. This combined modality therapy is also limited, in part, to the dose-limiting toxicities of the chemotherapeutic drugs [11, 13, 18] . 4 In comparison, clinical trials of MAbs alone have shown no dose-limiting toxicity up to 2,250 mg/m 2 [19] and 8 weekly doses [20] . Therefore, combination immunotherapy clinical trials have been conducted using rituximab with Hu1D10 (anti-HLA-DR) [21] , epratuzumab (anti-CD22) [22] , or Campath (anti-CD52) [23, 24] . A recent multicenter phase II trial of epratuzumab combined with rituximab in patients with refractory or recurrent non-Hodgkin's lymphoma showed promising anti-lymphoma activity and was well tolerated by patients [25] .
In the study reported here, we selected the combination of rituximab and chimeric Lym-1 (chLym-1 2 ), because of shared characteristics that offered remarkable potential. Although a single phase 1a trial of murine Lym-1 (mLym-1 6 ) failed to demonstrate substantial responses in patients, the dosages used and the plasma MAb levels achieved were significantly below those currently known to be required for effective MAb therapy [26] . However, both mLym-1 and chLym-1 have since been shown to have significant anti-tumor effects in in vitro assays [27] .
Both rituximab and chLym-1 have high affinity for the CD20 and HLA-DR antigens, respectively [28] [29] [30] [31] [32] . These antigens are attractive targets for immunotherapy, because they are expressed on a variety of B cell lymphomas at high surface densities, and are neither shed nor internalized following MAb binding [28, 33] . There is also evidence of physical and functional linkage between these molecules [22, 34, 35] Samples of MAbs were assayed for bacterial endotoxin, using a Limulus Amebocyte
Lysate test (Bio-wittaker Pyrogent plus, Walkersville, MD). The test was performed as previously described [38] . The levels of endotoxin in all MAb samples were negligible in our experimental system.
Cells
The human Burkitt's lymphoma cell lines, Raji and Ramos, were obtained from the American Type Culture Collection (Manassas, VA). The human Burkitt's lymphoma cell line, B35M, and the human large cell lymphoma cell lines, SU-DHL-4 and SU-DHL-6, were provided by Alan
Epstein. All cell lines were maintained in culture flasks with RMPI-1640 medium supplemented with 10% fetal bovine serum, 1% L-glutamine (200mM), 1% sodium pyruvate (100mM), 1% 7 nonessential amino acids and 1% penicillin/streptomycin at 37°C in a 5% CO 2 atmosphere. The CD20 and HLA-DR density of these cell lines was determined by rituximab and chLym-1, respectively, binding followed by a goat anti-human IgG-flourescein-isothiocyanate (FITC 7 ) and analyzed by fluorescence-activated cell sorting (FACS 8 ). All cell lines were found to have high expression of both CD20 and HLA-DR antigens with the exception of Ramos cells, which had high CD20 expression, but very low HLA-DR expression (data not shown).
Study Design
The direct effects of rituximab and Lym-1 alone and in combination were assayed in parallel in five cell lines. Equal amounts of rituximab and chLym-1 were added simultaneously in all combination samples. Untreated samples, with cells and media only, and those treated with nonspecific MAb, chL6, were included to provide baseline cell growth and death levels. To determine whether cell death was due to apoptosis, caspase-3 and poly (ADP-ribose) polymerase (PARP 9 ) activation were determined over 24 hours using Western blot assay and 10 μg/mL of MAb, a concentration that provided maximum direct anti-lymphoma effects. 8 Camptothecin, a topoisomerase inhibitor, known to induce apoptosis in hemopoietic cell lines, including Raji [39] , was used as a positive control and an untreated sample was used as a negative control. The relative ability of the MAbs alone and in combination to induce caspase-3
and PARP activation was compared to the camptothecin positive control, quantitated by densitometry, and expressed as the percent difference from the untreated control.
The indirect effects of rituximab and chLym-1 in combination and as single-agents, were assessed using ADCC and CDC assays. Since the ability of rituximab and chLym-1 to mediate ADCC has been shown to depend greatly on the types of effector cells used [10, 29, 40, 41] , each
MAb was assessed in the presence of all effector cells, and a broad range of MAb concentrations and cell lines were utilized.
In all assays, the combination MAb effect was considered to be synergistic if there was evidence that the combined MAb potency was greater than that of either MAb and one of the two MAbs was not potent when used alone [42] .
Assessment of Cell Number and Viability
Microscopy and trypan blue dye (960 kD) were used to determine cell number and viability at study time zero and after 24, 48, and 72 hours of incubation. B35M, SU-DHL-4, Raji, and
Ramos cells were at least 95% viable at study time zero; SU-DHL-6 cells were at least 90% viable at study time zero. To eliminate the influence of complement, cells in log phase of growth were centrifuged for 5 minutes at 1100 rpm to pellet the cells. The supernatant was removed and the cells resuspended in RPMI-1640 media supplemented with 10% heat inactivated fetal calf serum (HIFCS 10 ) and supplemental nutrients to twice their final concentration (5 x 10 5 cells/mL).
Similarly, rituximab + chLym-1, rituximab, chLym-1, and chL6 MAbs were diluted in the same media to twice their final concentration (single MAb concentration: 0.0005 μg/mL -50 μg/mL).
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Finally, 100 μl of cells were seeded into each well of a 96-well plate followed by addition of 100 μl of MAb or 100 μl of media for the untreated control and then incubated at 37°C in a humidified 5% CO 2 environment. At each time point, 90 μl of cells were removed from each well after gentle pipetting to break up cell aggregations. The aliquot of cells was then combined with 10 μl of filtered trypan blue. 10 μl of this mixture was then placed in a hemocytometer and counted using bright field microscopy, under which non-viable cells appeared blue and viable cells appeared bright and translucent. The numbers of viable and non-viable cells in each sample were summed to quantify the total population.
Caspase-3 and PARP Activation
The levels of caspase-3 and PARP activation products were determined by Western blot assay. at 37°C in a humidified 5% CO 2 environment, the tubes were centrifuged at 300g for 10 minutes.
One half of the supernatant was aliquoted, and the radioactivity was measured in a gamma counter. The percent lysis was determined by the following equation:
where E is the mean cpm released in the test samples with effector cells, H is the mean cpm released in the presence of 1N HCl, and T is the mean cpm released by target cells incubated with medium alone.
CDC Assay
The ability of 0.5 -12 μg/mL (single MAb concentration) rituximab and chLym-1, alone or in combination, to mediate CDC was assayed in duplicate and in parallel with the chL6 negative control. B35M, SU-DHL-4, Raji, and SU-DHL-6 cells were counted for viability and cell number using trypan blue exclusion and placed into RPMI-1640 medium containing no additives. The cells were immediately dispensed into round bottom, 96-well cell plates, with 1 million cells per well in 100 μl volume. 50 ul of MAb, diluted in RPMI-1640, was added,
followed by the addition of 50 μl of human serum obtained from a volunteer donor. After the plates were incubated for 1 hour at 37°C in a humidified 5% CO 2 environment, cell viability was determined by microsopy and trypan blue exclusion. 12 
Statistical Analysis
To assess the significance of the cell counts, a two sample, one-tailed, student T-test was performed on the duplicate counts within an experiment. Results were deemed significant if the p-value was equal to or less than 0.05. The Kendall Tau test was used to determine whether a significant concentration-response relationship existed. To assess whether this relationship was linear, Pearson's correlation was employed. A Pearson's product-moment correlation coefficient or a rank-order correlation coefficient for the Kendall Tau test of less than 0.05 was considered to be significant. To assess the difference between the treated and untreated samples, the percent difference observed in the numbers of replicate experiments (n = 2-3) were averaged. The difference was considered to be significant if the p-value was less than 0.05. 13 
RESULTS

Growth Inhibition and Cell Death
Using microscopy and trypan blue exclusion, the ability of rituximab and chLym-1 alone or in combination to induce growth inhibition and cell death was evaluated in the B35M, SU-DHL-4, 
Complement-Dependent Cytotoxicity (CDC)
The ability of rituximab and chLym-1 alone and in combination to mediate CDC against B35M, SU-DHL-4, Raji, and SU-DHL-6 cells was tested by comparing them with the untreated and chL6 negative controls ( Figure 6 ). Complement-mediated lysis due to the serum alone or the chL6 negative control was never greater than 10%. Although rituximab did not mediate CDC in B35M cells, its effect in combination with chLym-1 substantially increased the CDC effect over either MAb alone. At low concentrations of MAb, the effect due to combination treatment appeared to be synergistic. In SU-DHL-4, Raji, and SU-DHL-6 cells, rituximab alone mediated CDC more efficiently than chLym-1 alone, but no greater than the MAb combination (Table I) . 17 
DISCUSSION
In multiple human lymphoma cell lines expressing CD20 and HLA-DR antigens, we have demonstrated enhanced direct and indirect anti-lymphoma effects when rituximab and chLym-1 are used in combination. Using microscopy and trypan blue exclusion to distinguish viable from non-viable cells, greater direct anti-lymphoma effects were consistently observed in all cell lines given rituximab and chLym-1 in combination as opposed to equivalent doses of either MAb alone ( Table I) . The difference between the mono-and combination therapy seemed to be greatest in cell lines such as B35M and SU-DHL-4 that exhibited some resistance to either rituximab or chLym-1 alone. In these two cell lines, the effect of the MAb combination was synergistic in nature [42] . Stein et al. [43] similarly showed an enhanced anti-proliferative effect Interestingly, significant cell death was not observed in the SU-DHL-4 or SU-DHL-6 cell lines at any concentration of either MAb alone, or in combination, perhaps due to a t (14:18) chromosomal translocation in these cells leading to bcl-2 overexpression and inhibition of apoptosis that provided these cells with a survival advantage [44] . Since this mutation occurs in approximately 50% of NHLs (80% low grade; 30% intermediate grade), it seems likely that this gene plays a major role in MAb resistance. 18 In our study, Western blot assay showed increased caspase-3 and PARP activation in all rituximab and chLym-1 treated cell lines (B35M, SU-DHL-4, Raji, SU-DHL-6), indicating that ligation of HLA-DR or CD20 induced apoptosis, perhaps not exclusively, through a caspase-3 mediated pathway. Combination treatment induced greater apoptosis than rituximab or chLym-1 alone in all cell lines, but the effect was greatest in B35M cells in which caspase-3 activation by the combination was at least 4x greater than that of rituximab or chLym-1 alone and 6x greater than that of the untreated cells. These results suggest that the substantial cell death observed in B35M cells after combination treatment was due to synergistic induction of apoptosis.
In addition to direct anti-lymphoma effects, MAbs can activate indirect effector mechanisms, such as ADCC and CDC. In the presence of all peripheral effector cells, chLym-1 was more efficient than rituximab in mediating ADCC in all cell lines, consistent with the observation that anti-HLA-DR MAbs are potent activators of polymorphonuclear cells that represent the majority of effector cells normally in the blood [40, 41] . At all concentrations of
MAb and in all cell lines (B35M, SU-DHL-4, Raji, SU-DHL-6), the combination of rituximab and chLym-1 mediated at least as much ADCC as either MAb alone. Rituximab primarily induces ADCC effects in the presence of purified mononuclear cells [10] . Hence, the combination of rituximab and chLym-1 will take advantage of the cytotoxic capability of both mononuclear and polymorphonuclear effector cells. In addition, CDC assays, performed in the presence of human serum, showed a greater effect for the MAb combination compared to monotherapy in all cell lines. In B35M cells, the combination induced synergistic CDC effects whereas rituximab alone had no effect at any MAb concentration.
In this study of an anti-CD20 and an anti-HLA-DR MAb, neither MAb showed strong potency uniformly across all cell lines and assays (Table I) . However, the combination of rituximab and chLym-1 produced greater anti-lymphoma effects that were synergistic at times in cell lines that exhibited resistance to either MAb alone (Table I) . Past studies have shown a direct relationship between resistance to rituximab and low CD20 antigen density in cell lines [45] and in patients with B-chronic lymphocytic leukemia [46, 47] . In addition, rituximab treatment has also been associated with the loss or down-modulation of CD20 antigen expression [48] [49] [50] . To overcome resistance in patients with low CD20 levels, higher and more doses of rituximab have been used to increase response rates, although these responses have tended to be short-lived [51] .
In a previous study comparing another humanized anti-HLA-DR MAb with rituximab, Stein et al. [32] also showed that the combination of MAbs was more effective than rituximab alone. Synergy between anti-CD20 and anti-HLA-DR MAbs could be related to the physical and functional linkage of CD20 and HLA-DR antigens on B cells [22, 34, 35] . It is possible that the binding of one MAb to its antigen may directly affect the other MAb's binding, downstream molecular events, or antigen expression. It has been demonstrated in several studies that CD20 ligation with MAb redistributes the antigen into lipid rafts [52, 53] . Binding of rituximab to CD20 may then co-aggregate HLA-DR molecules as well as CD20 molecules on B cells.
Associating these molecules in close proximity increases the likelihood of antigen crosslinking by MAb, which has been shown to be necessary for significant rituximab-induced apoptosis [14, 54, 55] . The formation of lipid rafts is also required for the activation of certain HLA-DR signal transduction pathways [56, 57] . The mechanism of synergy between rituximab and chLym-1, therefore, may involve a dependent interaction of CD20 and HLA-DR molecules following combination immunotherapy. Studies of this nature are in progress. 20 Monoimmunotherapy is limited by variable and heterogenous antigen expression and the inevitability of drug resistance in an evolving biological system, whereas combination immunotherapy exploits the coexpression of distinct antigens and the possibility for synergy given the physical and functional linkages of those antigens, such as between CD20 and HLA-DR. Supporting combination immunotherapy, results for clinical trials of rituximab in combination with other MAbs (Hu1D10, epratuzumab, Campath) [21] [22] [23] [24] , have shown that it is safe, effective, and possibly synergistic in certain lymphoma histologies. Bispecific antibodies targeting two separate antigens are in development and promise to take advantage of combination immunotherapy, while minimizing cost and infusion times [58, 59] .
We have shown that combining rituximab and chLym-1 induces synergistic antilymphoma effects, such as growth inhibition, cell death, and apoptosis, while mediating greater indirect effects, such as ADCC and CDC, than monotherapy in all cell lines tested. Importantly, these effects were seen at MAb levels readily achievable in patients using the currently approved four, once weekly rituximab dosing [60] . * The effects in each assay were graded (0 to ++++) wherein an approximate linear estimation was made. Each (+) was assigned a particular percentage value for each effect indicated below. † (+) ≥ 300% decrease in viable cell population from the untreated after 72 h incubation. ‡ (+) ≥ 150% increase in the non-viable cell population from the untreated after 48 h incubation. § (+) ≥ 40% increase in activated caspase-3 from the untreated after 6 h incubation. ** (+) ≥ 15% specific lysis after 14 h incubation. † † (+) ≥ 15% specific lysis after 1 h incubation.
